CALT

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Learning Ally Presents Annual Spotlight on Dyslexia 2022

Retrieved on: 
Wednesday, May 11, 2022 - 1:49pm

PRINCETON, N.J., May 11, 2022 /PRNewswire/ -- Learning Ally, a national nonprofit and leading literacy education solutions provider, has announced its annual Spotlight on Dyslexia virtual conference. The two-day event will take place June 9th and 10th, 2022. It is designed for educators who want to deliver transformational change in student literacy outcomes in their districts, schools, and classrooms.

Key Points: 
  • PRINCETON, N.J., May 11, 2022 /PRNewswire/ -- Learning Ally, a national nonprofit and leading literacy education solutions provider, has announced its annual Spotlight on Dyslexia virtual conference .
  • Now in its seventh year, Spotlight on Dyslexia is one of the largest professional learning events in the United States.
  • "Educators who attend our Spotlight Learning Series and ongoing professional learning programming gain the knowledge necessary to begin the journey of becoming literacy leaders.
  • This year's Spotlight on Dyslexia event will celebrate educators receiving Learning Ally's 2022 National Achievement Awards.

Calliditas Therapeutics to participate in upcoming investor conferences

Retrieved on: 
Tuesday, May 10, 2022 - 7:44am

STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:

Key Points: 
  • STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:
    The 8thAnnual LSX World Congress on May 10-11, 2022 in London, United Kingdom
    The ABGSC Life Science Summit on May 18-19, 2022, in Stockholm, Sweden.
  • Management will be presenting and will host one-on-one investor meetings at the other three conferences.
  • To schedule a one-on-one meeting with Calliditas, please contact your representative at H.C Wainwright, Jefferies, or Citi.
  • Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Calliditas Therapeutics to participate in upcoming investor conferences

Retrieved on: 
Tuesday, May 10, 2022 - 7:43am

STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:

Key Points: 
  • STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:
    The 8thAnnual LSX World Congress on May 10-11, 2022 in London, United Kingdom
    The ABGSC Life Science Summit on May 18-19, 2022, in Stockholm, Sweden.
  • Management will be presenting and will host one-on-one investor meetings at the other three conferences.
  • To schedule a one-on-one meeting with Calliditas, please contact your representative at H.C Wainwright, Jefferies, or Citi.
  • Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Expansion of Everest Medicine's licence agreement to include South Korea

Retrieved on: 
Monday, March 14, 2022 - 6:24am

STOCKHOLM, March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) ("Everest") to extend the territory covered to include South Korea.

Key Points: 
  • STOCKHOLM, March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) ("Everest") to extend the territory covered to include South Korea.
  • "We continue to have a fruitful and positive collaboration with Everest and are delighted that we have come to an agreement also around South Korea," said CEO Rene Aguiar-Lucander.
  • The extension results in an upfront payment of USD 3 million to Calliditas as well as additional payments and royalties related to future potential approvals and commercialisation of Nefecon in South Korea.
  • Calliditas and Everest entered into a license agreement in 2019 to develop and commercialize Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN).

Expansion of Everest Medicine's licence agreement to include South Korea

Retrieved on: 
Monday, March 14, 2022 - 6:22am

STOCKHOLM, March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) ("Everest") to extend the territory covered to include South Korea.

Key Points: 
  • STOCKHOLM, March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) ("Everest") to extend the territory covered to include South Korea.
  • "We continue to have a fruitful and positive collaboration with Everest and are delighted that we have come to an agreement also around South Korea," said CEO Rene Aguiar-Lucander.
  • The extension results in an upfront payment of USD 3 million to Calliditas as well as additional payments and royalties related to future potential approvals and commercialisation of Nefecon in South Korea.
  • Calliditas and Everest entered into a license agreement in 2019 to develop and commercialize Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN).

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022 - 12:00am

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

Calliditas announces poster presentations at ASN Digital Kidney Week 2021

Retrieved on: 
Wednesday, November 3, 2021 - 8:42am

STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.

Key Points: 
  • STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.
  • In addition, Laura Prez-Als will present a poster titled "Treatment with Targeted Release Formulation Budesonide (Nefecon) Modulates the Complement System in Patients with IgA Nephropathy".
  • "We are delighted that these posters have been selected for the upcoming ASN Digital Kidney Week 2021 and congratulate the authors.
  • Calliditas is also planning to start clinical trials with NOX inhibitors in primary biliary cholangitis and head and neck cancer.

Calliditas announces poster presentations at ASN Digital Kidney Week 2021

Retrieved on: 
Wednesday, November 3, 2021 - 8:40am

STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.

Key Points: 
  • STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.
  • In addition, Laura Prez-Als will present a poster titled "Treatment with Targeted Release Formulation Budesonide (Nefecon) Modulates the Complement System in Patients with IgA Nephropathy".
  • "We are delighted that these posters have been selected for the upcoming ASN Digital Kidney Week 2021 and congratulate the authors.
  • Calliditas is also planning to start clinical trials with NOX inhibitors in primary biliary cholangitis and head and neck cancer.

Calliditas Therapeutics' nomination committee for the AGM 2022

Retrieved on: 
Tuesday, November 2, 2021 - 9:17am

publishes the nomination committee's composition for the AGM in 2022.

Key Points: 
  • publishes the nomination committee's composition for the AGM in 2022.
  • For more information please visit:
    Shareholders who wish to submit proposals to the nomination committee for the annual general meeting on May 31, 2022, can do so by e-mail to finance@calliditas.com .
  • Proposals should be submitted to the nomination committee before April 8, 2022.
  • Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT).